| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | J A Goldstein | |
| P2860 | cites work | cDNA and amino acid sequences of two members of the human P450IIC gene subfamily | Q24631075 |
| An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians | Q28137607 | ||
| A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin | Q28140035 | ||
| Identification of a new non-functional CYP2C18 allele in Japanese: substitution of T204 to A in exon2 generates a premature stop codon | Q71625126 | ||
| Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status | Q71993387 | ||
| Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects | Q71996229 | ||
| Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 | Q71996232 | ||
| The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study | Q72313200 | ||
| Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms | Q72415315 | ||
| Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8 | Q72710440 | ||
| Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments | Q73045816 | ||
| Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status | Q73369049 | ||
| CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates | Q73669215 | ||
| Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication | Q73697009 | ||
| Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes | Q73769600 | ||
| Genetic association between sensitivity to warfarin and expression of CYP2C9*3 | Q73834859 | ||
| Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype | Q74058615 | ||
| The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism | Q74222561 | ||
| No correlation between side-chain of propranolol oxidation and S-mephenytoin 4'-hydroxylase activity | Q74596634 | ||
| Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174 | Q74649851 | ||
| Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer | Q77732655 | ||
| CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans | Q77788807 | ||
| Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation | Q93613086 | ||
| Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese | Q28241420 | ||
| The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans | Q28254348 | ||
| A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin | Q28259441 | ||
| Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 | Q28270486 | ||
| Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin | Q28281837 | ||
| Biochemistry and molecular biology of the human CYP2C subfamily | Q28299258 | ||
| Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele | Q28307602 | ||
| Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele | Q28373588 | ||
| Complete nucleotide sequence of a methylcholanthrene-inducible cytochrome P-450 (P-450d) gene in the rat | Q28575566 | ||
| Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole | Q33734852 | ||
| Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark | Q34345510 | ||
| In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase | Q34346652 | ||
| The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study | Q34358893 | ||
| The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism | Q34735686 | ||
| Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro | Q35125188 | ||
| Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms | Q36053568 | ||
| Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population | Q36093868 | ||
| The gastric H+,K+-ATPase: the site of action of omeprazole | Q38313573 | ||
| Genetic polymorphism of S-mephenytoin hydroxylation | Q38692055 | ||
| High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. | Q39119071 | ||
| Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. | Q41931375 | ||
| The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype | Q42284719 | ||
| Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy | Q42547133 | ||
| The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase | Q42548432 | ||
| Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions | Q44735365 | ||
| Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate | Q45754897 | ||
| Genetic analysis of the cytochrome P-45OIIC18 (CYP2C18) gene and a novel member of the CYP2C subfamily | Q48064742 | ||
| Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. | Q51426110 | ||
| Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. | Q53459208 | ||
| Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans | Q57314135 | ||
| Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms | Q60678418 | ||
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications | Q63241969 | ||
| Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. | Q64923947 | ||
| Pharmacogenetics of tolbutamide metabolism in humans | Q67017361 | ||
| Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects | Q67832154 | ||
| The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine | Q68183654 | ||
| Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin | Q68994545 | ||
| Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities | Q69936283 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 349-55 | |
| P577 | publication date | 2001-10-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Clinical relevance of genetic polymorphisms in the human CYP2C subfamily | |
| P478 | volume | 52 |
| Q35888757 | A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics |
| Q35753523 | A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival |
| Q37959161 | A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management |
| Q50722759 | A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. |
| Q38730665 | ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib |
| Q36924687 | Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians |
| Q43265100 | Acute kidney injury in patients with inactive cytochrome P450 polymorphisms |
| Q37603880 | An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome P4502C9 in vivo activity. |
| Q57119190 | Animal models to study bile acid metabolism |
| Q36658236 | Antifungal prophylaxis following reduced-intensity stem cell transplantation |
| Q37708274 | Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers. |
| Q40220726 | Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes |
| Q33846255 | Applied pharmacogenomics in cardiovascular medicine |
| Q44828003 | Association between the CYP2C9 polymorphism and the drug metabolism phenotype |
| Q34306561 | Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans |
| Q36924724 | Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. |
| Q34635476 | BJCP 40th anniversary: moving forward, looking back. |
| Q34466778 | Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system |
| Q40575037 | Biomarkers for antiepileptic drug response |
| Q38357424 | Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer |
| Q36344158 | CYP2C19 genotype and the PPIs--focus on rabeprazole |
| Q44273424 | CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole |
| Q37140633 | CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors |
| Q45179286 | CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease. |
| Q44613016 | CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans |
| Q37676435 | CYP2C8 and CYP2C9 mRNA expression profile in the human fetus |
| Q46221248 | CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. |
| Q33990359 | CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies |
| Q44936830 | CYP2C9 genetic variants and losartan oxidation in a Turkish population. |
| Q42780491 | CYP2C9 polymorphism and warfarin dose requirements |
| Q34744094 | CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. |
| Q41631036 | CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy |
| Q36305439 | Cancer treatment and pharmacogenetics of cytochrome P450 enzymes |
| Q21284327 | Challenges in the association of human single nucleotide polymorphism mentions with unique database identifiers |
| Q30939373 | Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population |
| Q88869815 | Characterization of CYP2C Induction in Cryopreserved Human Hepatocytes and Its Application in the Prediction of the Clinical Consequences of the Induction |
| Q38505185 | Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes |
| Q44923699 | Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. |
| Q39667176 | Characterization of the genetic profile of CYP2C19 in two South African populations. |
| Q37959162 | Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse |
| Q36580034 | Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine |
| Q38431150 | Clinical association between pharmacogenomics and adverse drug reactions |
| Q35603768 | Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know |
| Q38823930 | Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations |
| Q40500349 | Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory |
| Q30395185 | Computational Analysis of Damaging Single-Nucleotide Polymorphisms and Their Structural and Functional Impact on the Insulin Receptor |
| Q36492939 | Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population |
| Q38099372 | Cytochrome P450 pharmacogenetics in African populations. |
| Q34612118 | Cytochrome P450 polymorphisms and response to antipsychotic therapy. |
| Q34491448 | Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations |
| Q38806725 | Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy. |
| Q33905508 | Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. |
| Q36573235 | Development of a genotyping tool for a functionally relevant CYP2C19 allele (Phe100Asn, Ala103Val and Ile112Leu) in cynomolgus macaques. |
| Q38655660 | Development of genotyping method for functionally relevant variants of cytochromes P450 in cynomolgus macaques |
| Q40917665 | Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect |
| Q45199695 | Development of primer-special TaqMan PCR: a novel SNP detection method to detect CYP2C9 3 in South Chinese |
| Q48151911 | Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug |
| Q37841723 | Developmental pharmacogenomics |
| Q37601039 | Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship |
| Q35876954 | Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms |
| Q57749415 | Distribution of CYP2C Polymorphisms in an Amerindian Population of Brazil |
| Q42324494 | Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. |
| Q34983154 | Drug-drug interaction between clopidogrel and the proton pump inhibitors. |
| Q36283721 | Drug-drug interactions of antifungal agents and implications for patient care |
| Q35890606 | Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature |
| Q38382592 | Effect of baseline characteristics on response to proton pump inhibitors in patients with peptic ulcer bleeding |
| Q49833189 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China |
| Q44593132 | Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects |
| Q42018917 | Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam |
| Q54172975 | Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. |
| Q92722908 | Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol |
| Q34352152 | Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease |
| Q42678199 | Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study |
| Q35988130 | Emerging strategies and applications of pharmacogenomics |
| Q82468735 | Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood |
| Q26998331 | Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy |
| Q33312876 | Expressed sequence tags from cynomolgus monkey (Macaca fascicularis) liver: a systematic identification of drug-metabolizing enzymes |
| Q46679743 | Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients |
| Q37024033 | Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model |
| Q36018001 | Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy. |
| Q35814384 | From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community |
| Q43066596 | Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions |
| Q37199426 | Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. |
| Q33358295 | Gene expression profiles in liver of pigs with extreme high and low levels of androstenone |
| Q54092302 | Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan. |
| Q43071574 | Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. |
| Q41624790 | Genetic Polymorphisms of Cytochrome P450 2C19 in Functional Dyspeptic Patients Treated with Cimetidine |
| Q44360560 | Genetic and environmental risk factors for oral anticoagulant overdose |
| Q35596195 | Genetic basis of age-dependent synaptic abnormalities in the retina |
| Q46619481 | Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study |
| Q57251500 | Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese |
| Q36375369 | Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population |
| Q44760870 | Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study |
| Q35825569 | Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations |
| Q85037693 | Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China |
| Q35753607 | Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers |
| Q36410400 | Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer |
| Q41859970 | Genetic polymorphisms, drug metabolism and drug concentrations. |
| Q43879115 | Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity |
| Q37599633 | Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal |
| Q38131848 | Genetics of platelet inhibitor treatment |
| Q37176949 | Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy |
| Q45058224 | Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region |
| Q36624080 | Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy |
| Q37904672 | Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. |
| Q33754808 | Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of CYP2C genes in primary cultures of human hepatocytes |
| Q41398712 | Heritability of metoprolol and torsemide pharmacokinetics |
| Q48030742 | High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis |
| Q36174736 | Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver |
| Q41487258 | Human Cytochrome P450 Enzyme Modulation by Gymnema sylvestre: A Predictive Safety Evaluation by LC-MS/MS |
| Q35070838 | Human pharmacogenomic variations and their implications for antifungal efficacy |
| Q35846595 | Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness |
| Q46119145 | Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. |
| Q37162165 | Identification of human CYP2C8 as a retinoid-related orphan nuclear receptor target gene |
| Q36909306 | Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans |
| Q37581626 | Impact of rat P450 genetic polymorphism on diazepam metabolism |
| Q23916231 | In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily |
| Q41946301 | In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda |
| Q44644004 | Induction of Human CYP2C9 by Rifampicin, Hyperforin, and Phenobarbital Is Mediated by the Pregnane X Receptor |
| Q43022498 | Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients |
| Q46724143 | Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae |
| Q46762942 | Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine |
| Q50449208 | Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases |
| Q46298744 | Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. |
| Q33908260 | Inhibition of Human Cytochrome P450 Enzymes by Allergen Removed Rhus verniciflua Stoke Standardized Extract and Constituents |
| Q44353604 | Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent |
| Q41155867 | Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4. |
| Q28292107 | Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam |
| Q36007599 | Interaction of warfarin with drugs, natural substances, and foods |
| Q47744170 | Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain |
| Q46523170 | Interspecies metabolic diversity of harmaline and harmine in in vitro 11 mammalian liver microsomes |
| Q38399837 | Intravenous Esomeprazole for Prevention of Peptic Ulcer Rebleeding: A Randomized Trial in Chinese Patients |
| Q36653603 | Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? |
| Q44897880 | Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers |
| Q44218965 | Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms |
| Q60705807 | Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations |
| Q45179972 | Linking pharmacovigilance with pharmacogenetics |
| Q36577254 | Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. |
| Q56794521 | Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender |
| Q46975102 | Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. |
| Q37202860 | Management of fungal infections following allogeneic stem cell transplantation |
| Q34938770 | Med25 is required for estrogen receptor alpha (ERα)-mediated regulation of human CYP2C9 expression |
| Q23920104 | Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4 |
| Q39582357 | Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma |
| Q38769649 | Monocrotophos Induces the Expression of Xenobiotic Metabolizing Cytochrome P450s (CYP2C8 and CYP3A4) and Neurotoxicity in Human Brain Cells |
| Q36094919 | Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. |
| Q33547147 | Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry |
| Q34852149 | NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes |
| Q57585710 | Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms |
| Q28477100 | Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey |
| Q46819416 | Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation |
| Q36475190 | Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects |
| Q38267499 | Nuclear hormone receptors PXR and CAR and metabolic diseases |
| Q37274199 | Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha |
| Q84018084 | Nuclear xenobiotic receptors: integrating gene regulation to physiological functions |
| Q35608859 | Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies |
| Q36995453 | PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics |
| Q42758765 | Personalized drug therapy; the genome, the chip and the physician |
| Q37772183 | Pharmacogenetics and human genetic polymorphisms |
| Q34458720 | Pharmacogenetics in Jewish populations. |
| Q26751138 | Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents |
| Q34181995 | Pharmacogenetics of Anti-Diabetes Drugs |
| Q35661209 | Pharmacogenetics of drug-metabolizing enzymes in US Hispanics |
| Q35067187 | Pharmacogenetics of the major polymorphic metabolizing enzymes. |
| Q35584999 | Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. |
| Q80577452 | Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations |
| Q35804222 | Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration |
| Q46605128 | Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population |
| Q27693916 | Poor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populations |
| Q37203893 | Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi |
| Q37163340 | Potential of pharmacokinetic profiling for detecting herbal interactions with drugs |
| Q34494596 | Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala. |
| Q38136990 | Proton pump inhibitors and clopidogrel: an association to avoid? |
| Q44983984 | QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. |
| Q46709200 | Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay |
| Q44534843 | Racial background is a determinant factor in the maintenance dosage of warfarin. |
| Q40389903 | Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors |
| Q43211983 | Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray |
| Q37162141 | Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test |
| Q46752709 | Reactive metabolite activation by CYP2C19-mediated rhein hepatotoxicity |
| Q28067682 | Regulation of drug-metabolizing enzymes by local and systemic liver injuries |
| Q34024630 | Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping. |
| Q54337089 | Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. |
| Q36076189 | Relative Copy Number Variations of CYP2C19 in South Indian Population |
| Q36478873 | Review article: acid-related disease--what are the unmet clinical needs? |
| Q37837981 | Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction |
| Q35923954 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole |
| Q47438997 | Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population |
| Q36097229 | Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism |
| Q35607530 | Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. |
| Q57177488 | Role of oxylipins in cardiovascular diseases |
| Q36249224 | Sarcomas and pharmacogenetics |
| Q46138029 | Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding? |
| Q46672840 | Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances |
| Q81010870 | Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis |
| Q34983639 | Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition |
| Q90175443 | Single-nucleotide polymorphism screening and RNA sequencing of key messenger RNAs associated with neonatal hypoxic-ischemia brain damage |
| Q80288931 | Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476 |
| Q35537682 | Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity |
| Q37039810 | Strength and weakness of phase I to IV trials, with an emphasis on translational aspects |
| Q46046369 | Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. |
| Q35585219 | Systemic Antifungal Therapy: New Options, New Challenges |
| Q35876022 | Technology platforms for pharmacogenomic diagnostic assays |
| Q43454795 | The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers |
| Q90252988 | The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production |
| Q48037601 | The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report |
| Q35826352 | The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding |
| Q46758734 | The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics |
| Q44649926 | The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children |
| Q35827277 | The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. |
| Q35827919 | The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects |
| Q39282924 | The emergence of new psychoactive substance (NPS) benzodiazepines: A review. |
| Q35062482 | The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. |
| Q34574033 | The pharmacogenomics of HIV therapy. |
| Q35827129 | The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel |
| Q36497088 | The role of genetic variability in drug metabolism pathways in breast cancer prognosis |
| Q33597311 | The transcriptional regulation of the human CYP2C genes |
| Q27009221 | Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective |
| Q35873687 | Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes |
| Q37945308 | Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. |
| Q44732685 | Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. |
| Q42696284 | Upregulation of human CYP2C9 expression by Bisphenol A via estrogen receptor alpha (ERα) and Med25. |
| Q35829133 | Using germ-line genetic variation to investigate and treat cancer |
| Q46522669 | Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population |
| Q48577491 | Voriconazole and fluconazole increase the exposure to oral diazepam |
| Q33946021 | Voriconazole: the newest triazole antifungal agent |
| Q37052185 | Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population. |
Search more.